Immunic Beats Expectations Despite Q3 Loss
Update: 2025-11-13
Description
Immunic Incorporated, a New York-based pharmaceutical firm, reported a net loss of $25.6 million for Q3, translating to a loss of $0.13 per share. Despite this loss, the companys performance exceeded analysts expectations, with actual results $0.05 better than the predicted $0.18 per share loss. This beat on expectations suggests a more favorable view of Immunics future prospects, indicating that while the company is still operating at a deficit, its financial situation is not as challenging as some experts had projected.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
